2/253/4208197 |
您所在的位置：网站首页 › 2/253/4208197 |
data-id="" iid="">PubMedhttps://pubmed.ncbi.nlm.nih.gov/28851764FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates ... - PubMed网页In the current study, we investigated the in vitro and in vivo pharmacologic activities of a novel GPR52 agonist, 4-(3-(3-fluoro-5-(trifluoromethyl)benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide (FTBMT). FTBMT functioned as a selective GPR52 agonist in vitro and in vivo, as demonstrated by the activation of Camp signaling in striatal ...
发布时间：2024-07-04data-id="" iid="">PubMedhttps://pubmed.ncbi.nlm.nih.gov/37925144Clinical Response and Remission in Patients With Severe …网页Anti-Asthmatic Agents. Biological Products. Clinical response was achieved in most adult patients initiating biologic therapy, and clinical remission was observed in 19% of the patients following 12 months of treatment. Further studies are required to assess the long-term outcome of achieving clinical remission with biologic therapy.
发布时间：2024-07-04data-id="" iid="">PubMedhttps://pubmed.ncbi.nlm.nih.gov/27879326Effects of levothyroxine treatment on pregnancy outcomes in ... - PubMed网页Background: Despite some studies indicating that thyroid antibody positivity during pregnancy has been associated with adverse pregnancy outcomes, evidence regarding the effects of levothyroxine (LT4) treatment of euthyroid/subclinical hypothyroid pregnant women with autoimmune thyroid disease on pregnancy outcome is limited. We aimed to assess …
发布时间：2024-07-04data-id="" iid="">Quran.comhttps://quran.com/2:253Quran.com网页Read and listen to Surah Al-Baqarah, verse 253, on Quran.com. Learn about the messengers that Allah favored and the miracles of Jesus.
发布时间：2024-07-04